| Vor Biopharma Inc. (VOR) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | |||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | |||||||||||||||||||||||||||||
| Operating Cash Flow | (22,801,000$) | (53,662,000$) | (35,184,000$) | (31,066,000$) | (24,063,000$) | (23,285,000$) | (21,847,000$) | (30,465,000$) | (24,026,000$) | (27,898,000$) | (24,100,000$) | (24,268,000$) | (18,346,000$) | (18,902,000$) | (24,992,000$) | (22,904,000$) | (17,587,000$) | (17,343,000$) | (16,565,000$) | (17,649,000$) | (13,634,000$) | (8,245,000$) | (8,328,000$) | (6,085,000$) | |||||||||||||||||||||||||
| Investing Cash Flow | (48,974,000$) | (244,000$) | 646,000$ | (230,000$) | (72,000$) | (34,000$) | 52,990,000$ | 43,973,000$ | 10,335,000$ | 40,536,000$ | 13,639,000$ | 6,498,000$ | (97,036,000$) | 12,702,000$ | (2,702,000$) | (7,055,000$) | (5,953,000$) | (8,486,000$) | (76,041,000$) | (1,171,000$) | (1,477,000$) | (1,587,000$) | (552,000$) | (545,000$) | |||||||||||||||||||||||||
| Purchases of Property and Equipment | 314,000$ | 244,000$ | 152,000$ | 231,000$ | 72,000$ | 34,000$ | 9,000$ | 114,000$ | 111,000$ | 465,000$ | 399,000$ | 94,000$ | 321,000$ | 298,000$ | 5,832,000$ | 2,011,000$ | 1,168,000$ | 636,000$ | 919,000$ | 1,171,000$ | 1,477,000$ | 1,587,000$ | 552,000$ | 545,000$ | |||||||||||||||||||||||||
| Financing Cash Flow | 307,799,000$ | 21,549,000$ | 175,065,000$ | (606,000$) | 53,286,000$ | 41,000$ | (31,000$) | 96,000$ | 25,000$ | 176,000$ | 218,000$ | 2,519,000$ | 112,261,000$ | 4,075,000$ | 604,000$ | 200,000$ | 307,000$ | 201,000$ | (445,000$) | 232,848,000$ | 46,000$ | 526,000$ | 64,192,000$ | 17,762,000$ | |||||||||||||||||||||||||
| End Cash Position | 396,486,000$ | 160,462,000$ | 190,574,000$ | 50,047,000$ | 81,949,000$ | 52,798,000$ | 76,076,000$ | 44,964,000$ | 31,360,000$ | 45,026,000$ | 32,212,000$ | 42,455,000$ | 57,706,000$ | 60,827,000$ | 62,952,000$ | 90,042,000$ | 119,801,000$ | 143,034,000$ | 169,516,000$ | 262,567,000$ | 48,539,000$ | 63,604,000$ | 72,910,000$ | ||||||||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (23,115,000$) | (53,906,000$) | (35,336,000$) | (31,297,000$) | (24,135,000$) | (23,319,000$) | (21,856,000$) | (30,579,000$) | (24,137,000$) | (28,363,000$) | (24,499,000$) | (24,362,000$) | (18,667,000$) | (19,200,000$) | (30,824,000$) | (24,915,000$) | (18,755,000$) | (17,979,000$) | (17,484,000$) | (18,820,000$) | (15,111,000$) | (9,832,000$) | (8,880,000$) | (6,630,000$) | |||||||||||||||||||||||||